Sage Therapeutics, Inc. - Common Stock (SAGE)

Sage Therapeutics, Inc. (NASDAQSAGE), today announced that it will host a live webcast on Tuesday, February 11, 2025 at 4:30 p.m. ET to review fourth quarter and full year 2024 financial results and discuss recent business updates.

Sage Therapeutics, Inc. (Nasdaq: SAGE) (“Sage” or “the Company”), today announced that its Board of Directors has initiated a process to explore strategic alternatives for the Company. The Board intends to evaluate a broad range of opportunities to maximize value for shareholders, including but not limited to a potential strategic transaction, business combination or sale.

As 2025 kicks off, several companies are standing out as stocks to watch, driven by groundbreaking technologies, strategic market positioning, and strong growth potential. From cutting-edge oncology treatments to defense technology innovations and wellness solutions, these companies are making waves across various sectors. Here's a closer look at stocks like Phio Pharmaceuticals (NASDAQPHIO), LightPath Technologies NASDAQ: LPTHNASDAQLPTH)(NASDAQ: KAVLNASDAQKAVL, and more, making headlines and capturing investor attention.

Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Chief Executive Officer Barry Greene will discuss the Company’s strategic focus areas for 2025 at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California.

Sage Therapeutics, Inc. (Nasdaq: SAGE) (“The Company”), today confirmed that Biogen Inc. (Nasdaq: BIIB) (“Biogen”) has submitted to the Company an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share.

Sage Therapeutics, Inc. (NASDAQSAGE) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 8:15 a.m. PT in San Francisco, CA.

Sage Therapeutics, Inc. (NASDAQSAGE), today announced that the Company will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024, at 9:00 a.m. ET in New York, NY.

Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced topline results from the Phase 2 DIMENSION Study of dalzanemdor (SAGE-718) in participants with cognitive impairment (CI) associated with Huntington’s Disease (HD). In the study, dalzanemdor did not demonstrate a statistically significant difference versus placebo on the primary endpoint, the change from baseline on the Symbol Digit Modalities Test (SDMT) at Day 84. Analyses of secondary endpoints did not demonstrate statistically significant or clinically meaningful differences in participants treated with dalzanemdor compared to placebo. Based on these results, the Company does not plan further development of dalzanemdor.

Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the third quarter ended September 30, 2024.

The Law Offices of Frank R. Cruz reminds investors of the upcoming October 28, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Sage Therapeutics, Inc. (“Sage” or the “Company”) (NASDAQSAGE) securities between April 12, 2021 and July 23, 2024, inclusive (the “Class Period”).

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers and acquirers of Sage Therapeutics, Inc. (NASDAQSAGE) securities between April 12, 2021 and July 23, 2024, both dates inclusive (the “Class Period”). Sage Therapeutics is a biopharmaceutical company that develops and commercializes brain health medicines.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Sage To Contact Him Directly To Discuss Their Options

NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Methode Electronics Inc. (NYSEMEI), Starbucks Corporation NASDAQ:SBUXNASDAQSBUX)(NYSE: DAVANYSEDAVA, and Sage Therapeutics, Inc. (NASDAQ: SAGENASDAQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

Sage Therapeutics, Inc. (Nasdaq: SAGE), today announced a strategic reorganization of its business operations to support the ongoing launch of ZURZUVAE in postpartum depression and focus pipeline development efforts ahead of a clinical study readout for dalzanemdor in Huntington’s Disease expected later this year. The reorganization is intended to enable Sage to strengthen its balance sheet, extend cash runway, and position the company for long-term growth potential.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Sage To Contact Him Directly To Discuss Their Options

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Outset Medical, Inc. (NASDAQOM), Starbucks Corporation NASDAQ:SBUXNASDAQSBUX)(NYSE: DAVANYSEDAVA, and Sage Therapeutics, Inc. (NASDAQ: SAGENASDAQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Sage Therapeutics, Inc. (NASDAQSAGE), today announced that it will host a live webcast on Tuesday, October 29, 2024 at 4:30 p.m. ET to review third quarter 2024 financial results and discuss recent business updates.

NEW YORK, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Sage To Contact Him Directly To Discuss Their Options

NEW YORK, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Outset Medical, Inc. (NASDAQOM), Starbucks Corporation NASDAQ:SBUXNASDAQSBUX)(NYSE: DAVANYSEDAVA, and Sage Therapeutics, Inc. (NASDAQ: SAGENASDAQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Sage Therapeutics, Inc. (Nasdaq: SAGE) announced today topline results from LIGHTWAVE, a 12-week, Phase 2 randomized, double-blind, placebo-controlled study to evaluate the effects of dalzanemdor (SAGE-718) in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s Disease (AD). The LIGHTWAVE Study did not demonstrate a statistically significant difference from baseline in participants treated with dalzanemdor versus placebo on the Wechsler Adult Intelligence Scale Fourth Edition (WAIS-IV) Coding Test score at Day 84, the primary outcome measure of the study.

NEW YORK, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

NEW YORK, Oct. 06, 2024 (GLOBE NEWSWIRE) --

NEW YORK, Oct. 05, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Outset Medical, Inc. (NASDAQOM), Starbucks Corporation NASDAQ:SBUXNASDAQSBUX)(NYSE: DAVANYSEDAVA, and Sage Therapeutics, Inc. (NASDAQ: SAGENASDAQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.